Score
2
2000
pubmed
[Immunocorrective effect of cycloferon and thymogen in patients with uterine cancer].
Antipova. S V SV
Key Findings
- Uterine cancer patients show significant immune disturbances before surgery
- Thymogen (with cycloferon) normalizes immune status markers
- Treated patients experienced a more favorable postoperative course
Practical Outcomes
- Thymogen appears to have immune‑modulating effects in a clinical cancer setting, but the data are limited to a specific patient group and surgical context. For biohackers, it suggests potential immune support, yet there isn’t enough evidence to recommend it for general longevity, metabolic health, or performance protocols without further research.
Summary
In a study of women with uterine cancer, giving the peptide thymogen (along with cycloferon) helped bring their immune system markers back to normal and was linked to smoother recovery after surgery.
Abstract
Those women diagnosed as having hysterocarcinoma demonstrate even before surgery pronounced immunological disturbances tending to progress after surgical intervention. The employment of cyclopheronum and thymogenum makes for normalization of values for the immune status. Clinically, this is accompanied by a more favourable postoperative course.
Study Information
Provider
pubmed
Year
2000